PMC:7536913 / 10430-11498
Annnotations
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T29 | 177-224 | Disease | denotes | severe acute respiratory syndrome coronavirus 2 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T30 | 177-210 | Disease | denotes | severe acute respiratory syndrome | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T31 | 226-230 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T54 | 145-148 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
| T55 | 452-453 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T56 | 590-592 | http://purl.obolibrary.org/obo/CLO_0008935 | denotes | S9 |
| T57 | 857-858 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T58 | 967-974 | http://purl.obolibrary.org/obo/NCBITaxon_33208 | denotes | animals |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T7 | 66-70 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T8 | 986-990 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 92 | 177-224 | Species | denotes | severe acute respiratory syndrome coronavirus 2 | Tax:2697049 |
| 93 | 358-366 | Species | denotes | patients | Tax:9606 |
| 94 | 1052-1060 | Species | denotes | patients | Tax:9606 |
| 95 | 226-235 | Species | denotes | SARS‐CoV2 | Tax:2697049 |
| 96 | 586-589 | Disease | denotes | ICH | MESH:D002543 |
| 97 | 889-892 | Disease | denotes | ICH | MESH:D002543 |
LitCovid-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T5 | 713-721 | Phenotype | denotes | oncology | http://purl.obolibrary.org/obo/HP_0002664 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T69 | 0-42 | Sentence | denotes | Risk‐based preclinical safety requirements |
| T70 | 43-367 | Sentence | denotes | The global support for drug and vaccine development, including streamlining nonclinical requirements, has allowed candidates, such as severe acute respiratory syndrome coronavirus 2 (SARS‐CoV2) antibodies, to move quickly into the clinic to most efficiently determine if the experimental treatment is effective for patients. |
| T71 | 368-585 | Sentence | denotes | The practice of deferring or eliminating certain preclinical studies while there is a degree of uncertainty in the experimental candidate for specific life‐threatening illnesses with no effective treatment is not new. |
| T72 | 586-734 | Sentence | denotes | ICH S9 Guideline “Nonclinical Evaluation for Anticancer Pharmaceuticals” provides for such regulatory flexibility for advanced oncology indications. |
| T73 | 735-893 | Sentence | denotes | We encourage regulators to apply this approach to other life‐threatening illnesses across therapeutic areas, and to model a global harmonized approach as ICH. |
| T74 | 894-1068 | Sentence | denotes | The benefits to society could be significant—by reducing the need to use animals, modernize drug development, and potentially make new therapies available to patients faster. |